Use of Recombinant Factor VIIA as a Risk Factor for Graft Loss after Orthotopic Liver Transplantation Due to Hepatic Artery Thrombosis
Background: The genetically engineered recombinant activated factor VII (rFVIIa) was primarily developed
Articles, journals and conferences in one search. An exact title, DOI or ISSN is listed first.
In the search box: "exact phrase" · -leave out · OR · prefix* · title: author: journal:
Background: The genetically engineered recombinant activated factor VII (rFVIIa) was primarily developed
Hind Bafaqih and Farah Thabet PDF Share this article
Patients were stratified into three treatment groups dependent upon which CFC was administered: recombinant factor VIIa (rfVIIa), three factor prothrombin complex concentrate (3F-PCC)/rfVIIa, or four factor prothrombin…
Hemorrhagic stroke which is a form of stroke that affects 20% of
factor VII deficiency. Case: Patient’s factor VII levels were determined. We administered recombinant factor VIIa, two hours prior to surgery. Repeat sample for coagulation profile was taken 1 hour ... surgery was…
platelet function tests were completely disturbed. Injections of fresh frozen plasma, recombinant coagulation factor VIIa, protrombin complex, vitamin K and platelet plasma were applied. As a result of extensive…
replenishing factor X and II with FFP/Prothrombinex. If bleeding continues, consider using activated factor VIIa
tranexamic acid, are discussed. Specific correction of coagulation using fresh frozen plasma, cryoprecipitate or factor VIIa may be required. The multimodality approach to blood loss aims to optimize outcomes
IABP). The coagulopathy was treated with packed red cells, Platelets, FFP, cryoprecipitate and recombinant factor VIIa transfused and titrated with point-of-care testing using Thromboelastography. The woman’s recovery
from the surgical interventions. It is regularly controlled by medical therapies (including; systemic recombinant factor VIIa, local anti-fibrinolytic agents and blood/platelet transfusions) and surgical therapies…
treatment of bleeding is with a bypassing agent. Two available licensed regimens are recombinant factor VIIa and the activated prothrombin complex concentrate. The risk of severe life-threatening bleeding continues
treatment of bleeding is with a bypassing agent. Two available licensed regimens are recombinant factor VIIa and the activated prothrombin complex concentrate. The risk of severe life-threatening bleeding continues
activated protein kinase kinase (MEK) inhibitor, a connective tissue growth factor inhibitor, a coagulase factor VIIa inhibitor, as well as adenovirus delivery of herpes simplex virus thymidine synthase gene followed
Tissue factor (coagulation factor III) is a cell surface receptor for coagulation factor VII/VIIa; it was initially recognized as an initiator of the extrinsic coagulation pathway. Recently, the zebrafish
glycoprotein tissue factor (TF) to the flowing blood. Once exposed, TF binds factor VII/VIIa (FVII/FVIIa) and in presence of calcium ions, it forms atertiary complex able to activate ... been considered only as cell…
indicates that preoperative fibrinogen plasma concentration, even within the normal range, is a limiting factor for haemostasis after cardiac surgery. In theory, fibrinogen might induce a risk for thrombosis ... with…
The aim of this study was to identify potential markers of atherosclerosis
For authors and organisers
Find the right journal for your paper and submit your manuscript.